7. Prevalence of Current, 12-Month, and Lifetime Major Depressive Disorder among Patients with Systemic Sclerosis.

Lisa R. Jewett, Ilya Razykov, Marie Hudson, Murray Baron, Brett D. Thombs, and the Canadian Scleroderma Research Group. 
Departments of 1Educational and Counseling Psychology; 2Psychiatry; 3Epidemiology, Biostatistics, and Occupational Health; and 4Medicine; and 5School of Nursing, McGill University, Montréal, Québec, Canada; 6Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Montréal, Québec, Canada.

Objectives: Patients with systemic sclerosis (scleroderma, or SSc) experience a range of problems affecting their quality of life, but only one small study has assessed the prevalence of major depressive disorder (MDD) in SSc. The objectives of this study were: (i) to assess the prevalence of current (30-day), 12-month, and lifetime MDD in a large sample of Canadian SSc patients; and (ii) to investigate socio-demographic and disease factors associated with 12-month MDD.

Methods: SSc patients were recruited from seven Canadian Scleroderma Research Group Registry sites (April 2009 to May 2012). MDD and history of a prior depression episode (major or minor) were assessed with the Composite International Diagnostic Interview.

Results: Among 345 patients, prevalence of 30-day, 12-month, and lifetime MDD was 3.8% (95% CI 2.2%, 6.3%; n = 13), 10.7% (95% CI 7.9%, 14.4%; n = 37) and 22.9% (95% CI 18.8%, 27.6%; n = 79), respectively. Patients with 12-month MDD had more severe gastrointestinal tract involvement than patients without 12-month MDD, but there were no other significant differences on socio-demographic or disease variables. Among patients with 12-month MDD, 81.1% (95% CI 65.8%, 90.3%) reported a prior depression episode compared with 3.9% (95% CI 2.2%, 6.7%) among patients without 12-month MDD (p<0.01).

Conclusion: The prevalence of 30-day, 12-month and lifetime MDD among Canadian SSc patients is approximately twice that of the Canadian general population and somewhat higher than in arthritis patients. SSc patients face a range of psychosocial problems and may benefit from a broad supportive care approach.